142 related articles for article (PubMed ID: 12454555)
21. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.
Li X; Zhu L; Su Y; Fang S
PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121
[TBL] [Abstract][Full Text] [Related]
22. Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.
Lydiard RB; Pitrosky B; Hackett D; White C
J Clin Psychiatry; 2004 Jun; 65(6):838-44. PubMed ID: 15291662
[TBL] [Abstract][Full Text] [Related]
23. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
24. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
[TBL] [Abstract][Full Text] [Related]
25. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
Nicolini H; Bakish D; Duenas H; Spann M; Erickson J; Hallberg C; Ball S; Sagman D; Russell JM
Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.
Montgomery SA; Sheehan DV; Meoni P; Haudiquet V; Hackett D
J Psychiatr Res; 2002; 36(4):209-17. PubMed ID: 12191625
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.
Stein MB; Pollack MH; Bystritsky A; Kelsey JE; Mangano RM
Psychopharmacology (Berl); 2005 Jan; 177(3):280-8. PubMed ID: 15258718
[TBL] [Abstract][Full Text] [Related]
28. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective.
Vera-Llonch M; Dukes E; Rejas J; Sofrygin O; Mychaskiw M; Oster G
Eur J Health Econ; 2010 Feb; 11(1):35-44. PubMed ID: 19506926
[TBL] [Abstract][Full Text] [Related]
30. Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.
Pae CU; Lim HK; Ajwani N; Lee C; Patkar AA
Expert Rev Neurother; 2007 Jun; 7(6):603-15. PubMed ID: 17563244
[TBL] [Abstract][Full Text] [Related]
31. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
Simon JS; Aguiar LM; Kunz NR; Lei D
J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
33. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.
Allgulander C; Nutt D; Detke M; Erickson J; Spann M; Walker D; Ball S; Russell J
J Psychopharmacol; 2008 Jun; 22(4):417-25. PubMed ID: 18635722
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
Rynn MA; Riddle MA; Yeung PP; Kunz NR
Am J Psychiatry; 2007 Feb; 164(2):290-300. PubMed ID: 17267793
[TBL] [Abstract][Full Text] [Related]
35. Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder.
Kim TS; Pae CU; Yoon SJ; Bahk WM; Jun TY; Rhee WI; Chae JH
Psychiatry Clin Neurosci; 2006 Jun; 60(3):347-51. PubMed ID: 16732752
[TBL] [Abstract][Full Text] [Related]
36. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.
Entsuah R; Gorman JM
J Psychiatr Res; 2002; 36(3):111-8. PubMed ID: 11886688
[TBL] [Abstract][Full Text] [Related]
37. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Perugi G; Frare F; Toni C; Ruffolo G; Torti C
Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of short-term venlafaxine XR therapy for GAD. Results of short-term, double-blind, placebo-controlled trials.
Feighner J
Postgrad Med; 1999 Nov; 106(6 Suppl):10-6. PubMed ID: 19667499
[TBL] [Abstract][Full Text] [Related]
39. Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.
Meoni P; Hackett D; Lader M
Depress Anxiety; 2004; 19(2):127-32. PubMed ID: 15022148
[TBL] [Abstract][Full Text] [Related]
40. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder.
Hackett D; Haudiquet V; Salinas E
Eur Psychiatry; 2003 Jun; 18(4):182-7. PubMed ID: 12814852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
